Monobenzyl Ether of Hydroquinone in Depigmentation of Vitiligo. - Trial PACTR201808699550182
Access comprehensive clinical trial information for PACTR201808699550182 through Pure Global AI's free database. This Phase 4 trial is sponsored by Vitiligo unit Dermatology department Cairo university and is currently Completed. The study focuses on Skin and Connective Tissue Diseases.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vitiligo unit Dermatology department Cairo university
Timeline & Enrollment
Phase 4
Nov 30, 2016
May 30, 2018
Summary
Background: Depigmentation presents a final alternative for patients with widespread vitiligo, failing to attain satisfactory pigmentation and having a compromised quality of life (QOL). Monobenzyl Ether of Hydroquinone (MBEH) is the most widely used topical preparation for depigmentation but little is known regarding specific features of its utilization. Objective: Evaluating and comparing two concentrations of MBEH cream (20% & 40%) regarding their efficacy, tolerability and effect on patients’ QOL.
ICD-10 Classifications
Data Source
Pan Africa Clinical Trials Registry
PACTR201808699550182
Non-Device Trial